Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MGC-026 by MacroGenics for Cervical Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According to...
MGC-026 by MacroGenics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
MGC-026 by MacroGenics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to...
MGC-026 by MacroGenics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
MGC-026 by MacroGenics for Metastatic Ovarian Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, Phase...
MGC-026 by MacroGenics for Metastatic Colorectal Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
MGC-026 by MacroGenics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...
MGC-026 by MacroGenics for Non-Small Cell Lung Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
MGC-026 by MacroGenics for Endometrial Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Gastric Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Solid Tumor: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Sarcomas: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs...
MGC-026 by MacroGenics for Metastatic Pancreatic Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase...
MGC-026 by MacroGenics for Metastatic Melanoma: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Small-Cell Lung Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...
MGC-026 by MacroGenics for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
MGC-026 by MacroGenics for Metastatic Breast Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase...
MGC-026 by MacroGenics for Bladder Cancer: Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I...
MGC-026 by MacroGenics for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
MGC-026 is under clinical development by MacroGenics and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to...